Skip to main content
SpringerLink
Log in

Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare Hodgkin lymphoma distinguished from classical Hodgkin lymphoma (cHL) by the nature of the neoplastic cells which express B-cell markers. We wanted to determine the diagnostic performance of FDG PET/CT in initial assessment and its therapeutic impact on staging.

Methods

We retrospectively studied a population of 35 patients with NLPHL (8 previously treated for NLHPL, 27 untreated). All patients underwent an initial staging by pretherapeutic FDG PET/CT. The impact on initial stage or relapse stage was assessed by an independent physician.

Results

In a per-patient analysis, the sensitivity of the pretherapeutic FDG PET/CT was 100 %. In a per-site analysis, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of pretherapeutic FDG PET/CT were 100 %, 99 %, 97 %, 100 % and 99 %, respectively. Pretherapeutic FDG PET/CT led to a change in the initial stage/relapse stage in 12 of the 35 patients (34 %). In contrast to previous results established without FDG PET/CT, 20 % of patient had osteomedullary lesions.

Conclusion

Pretherapeutic FDG PET/CT has excellent performance for initial staging or relapse staging of NLPHL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jost LM, Stahel RA; ESMO Guidlines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin’s disease. Ann Oncol. 2005;16 Suppl 1:i54–5.

    Article  PubMed  Google Scholar 

  2. Braeuninger S, Kueppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte predominance Hodgkin disease represent clonal populations of germinal center derived tumor cells. Proc Natl Acad Sci U S A. 1997;94(17):9337–42.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon: IARC; 2008.

    Google Scholar 

  4. Mason DY, Banks PM, Chan J, Cleary ML, Delsol G, de Wolf Peeters C, et al. Nodular lymphocyte predominance Hodgkin’s disease: a distinct clinicopathological entity. Am J Surg Pathol. 1994;18(5):526–30.

    Article  PubMed  CAS  Google Scholar 

  5. Marafioti T, Pozzobon M, Hansmann ML, Delsol G, Pileri SA, Mason DY. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood. 2004;103(1):188–93.

    Article  PubMed  CAS  Google Scholar 

  6. Atayar C, Poppema S, Visser L, van den Berg A. Cytokine gene expression profile distinguishes CD4/CD57 T cells of the nodular lymphocyte predominance type of Hodgkin’s lymphoma from their tonsillar counterparts. J Pathol. 2006;208(3):423–30.

    Article  PubMed  CAS  Google Scholar 

  7. Hansmann ML, Zwingers T, Böske A, Löffler H, Lennert K. Clinical features of nodular paragranuloma (Hodgkin’s disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol. 1984;108(3):321–30.

    Article  PubMed  CAS  Google Scholar 

  8. Mauch PM, Kalish LA, Kadin M, Coleman CN, Osteen R, Hellman S. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer. 1993;71(6):2062–71.

    Article  PubMed  CAS  Google Scholar 

  9. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol. 1999;17(3):776–83.

    PubMed  CAS  Google Scholar 

  10. Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin’s disease. J Clin Oncol. 1997;15(9):3060–6.

    PubMed  CAS  Google Scholar 

  11. Crennan E, D’Costa I, Liew KH, Thompson J, Laidlaw C, Cooper I, et al. Lymphocyte predominant Hodgkin’s disease: a clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys. 1995;31(2):333–7.

    Article  PubMed  CAS  Google Scholar 

  12. Pappa VI, Norton AJ, Gupta RK, Wilson AM, Rohatiner AZ, Lister TA. Nodular type of lymphocyte predominant Hodgkin’s disease. A clinical study of 50 cases. Ann Oncol. 1995;6(6):559–65.

    PubMed  CAS  Google Scholar 

  13. Al-Mansour M, Connors J, Gascoyne R, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol. 2010;28(5):793–9.

    Article  PubMed  Google Scholar 

  14. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997;203(3):795–800.

    Article  PubMed  CAS  Google Scholar 

  15. Bangerter M, Moog F, Buchmann I. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol. 1998;9(10):1117–22.

    Article  PubMed  CAS  Google Scholar 

  16. Menzel C, Döbert N, Mitrou P, Mose S, Diehl M, Berner U, et al. Positron emission tomography for the staging of Hodgkin’s lymphoma. Acta Oncol. 2002;41(5):430–6.

    Article  PubMed  Google Scholar 

  17. Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematol. 2002;81(1):20–5.

    Article  PubMed  CAS  Google Scholar 

  18. Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, et al. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med. 2008;113(4):578–90. doi:10.1007/s11547-008-0264-7.

    Article  PubMed  CAS  Google Scholar 

  19. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.

    Article  PubMed  Google Scholar 

  20. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.

    Article  PubMed  Google Scholar 

  21. Lopci E, Zanoni L, Chiti A, Fonti C, Santi I, Zinzani PL, et al. FDG PET/CT predictive role in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2012;39(5):864–71. doi:10.1007/s00259-012-2079-y.

    Article  PubMed  Google Scholar 

  22. Le Dortz L, De Guibert S, Bayat S, Devillers A, Houot R, Rolland Y, et al. Diagnostic and prognostic impact of 18 F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307–14. doi:10.1007/s00259-010-1539-5.

    Article  PubMed  Google Scholar 

  23. Döbert N, Menzel C, Grünwald F. Positron emission tomography in patients with Hodgkin’s disease: correlation to histopathologic subtypes. Cancer Biother Radiopharm. 2003;18(4):565–71.

    Article  PubMed  Google Scholar 

  24. Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol. 2006;24(3):146–50.

    Article  PubMed  CAS  Google Scholar 

  25. Ansquer C, Hervouët T, Devillers A, de Guibert S, Gastinne T, Le Gouill S, et al. 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease. Haematologica. 2008;93(1):128–31. doi:10.3324/haematol.11661.

    Article  PubMed  Google Scholar 

  26. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(21):4643–51.

    Article  PubMed  Google Scholar 

  27. Rüdiger T, Gascoyne RD, Jaffe ES, de Jong D, Delabie J, De Wolf-Peeters C, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin’s lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol. 2002;13 Suppl 1:44–51.

    Article  PubMed  Google Scholar 

  28. Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 2010;116(3):631–9.

    Article  PubMed  Google Scholar 

  29. Chera BS, Olivier K, Morris CG, Lynch JW, Mendenhall NP. Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida. Am J Clin Oncol. 2007;30(6):601–6.

    Article  PubMed  Google Scholar 

  30. Nogová L, Reineke T, Josting A, Müller-Hermelink HK, Eich HT, Behringer K, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma – comparison of outcomes. Eur J Haematol. 2005;75 Suppl s66:106–110.

    Article  Google Scholar 

  31. Feugier P, Labouyrie E, Djeridane M, Jenabian A, Dubruille V, Berthou C, et al. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood. 2004;104(9):2675–81.

    Article  PubMed  CAS  Google Scholar 

  32. Orlandi E, Lazzarino M, Brusamolino E, Paulli M, Astori C, Magrini U, et al. Nodular lymphocyte predominance Hodgkin’s disease: long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma. 1997;26(3-4):359–68.

    PubMed  CAS  Google Scholar 

  33. Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101(11):4285–9.

    Article  PubMed  CAS  Google Scholar 

  34. Shankar A, Hall GW, Gorde-Grosjean S, Hasenclever D, Leblanc T, Hayward J, et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma – an Anglo-French collaborative report. Eur J Cancer. 2012;48(11):1700–6.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. AP-HP- Hôpital Européen Georges Pompidou, Service de médecine nucléaire, Paris, 75015, France

    Jean François Grellier & Pierre Weinmann

  2. AP-HP- Hôpital Saint-Louis, Service de médecine nucléaire, Paris, 75010, France

    Laetitia Vercellino, Pascal Merlet, Marie-Elisabeth Toubert & Nathalie Berenger

  3. Hôpital Saint-Louis, Service d’immuno-hématologie, Paris, 75010, France

    Thierry Leblanc

  4. AP-HP- Hôpital Saint-Louis, Service d’hémato-Oncologie, Université Paris Diderot, Sorbonne Paris Cité – INSERM UMR_S1165, Paris, 75010, France

    Catherine Thieblemont

  5. AP-HP- Hôpital Saint-Louis, Service de pathologie, Paris, 75010, France

    Josette Brière

  6. AP-HP- Hôpital Saint-Louis, Service d’hémato-Oncologie, Paris, 75010, France

    Pauline Brice

Authors
  1. Jean François Grellier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laetitia Vercellino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thierry Leblanc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pascal Merlet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Catherine Thieblemont
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pierre Weinmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marie-Elisabeth Toubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nathalie Berenger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Josette Brière
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pauline Brice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean François Grellier.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grellier, J.F., Vercellino, L., Leblanc, T. et al. Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41, 2023–2030 (2014). https://doi.org/10.1007/s00259-014-2825-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-014-2825-4

Keywords

Search

Navigation